Liminatus Pharma, Inc. Class A Common Stock
LIMN XNAS
$0.14
+0.00 (+0.00%)
▲
15-min delayed
Open
N/A
High
N/A
Low
N/A
Volume
N/A
Market Cap
$7.21M
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0 | $-1,123,714 | $-0.03 |
| FY 2025 | $0 | $-10,206,517 | $-0.43 |
| Q3 2025 | $0 | $-1,823,351 | $-0.07 |
| Q2 2025 | $0 | $113.3K | $0.00 |
TickerDaily Coverage
Why Is Liminatus Pharma, Inc. Class A Common Stock (LIMN) Stock Up 53.4% Today?
Penny Stocks
Marcus Rivera · 3d ago
Liminatus Pharma (LIMN) stock exploded 53.4% higher on Thursday, July 2, 2026, closing at $0.176...
Why Is Liminatus Pharma, Inc. Class A Common Stock (LIMN) Stock Up 64.7% Today?
Penny Stocks
Marcus Rivera · May 21, 2026
Liminatus Pharma stock exploded higher Thursday after the company announced a proposed merger with...
Stock Market Today, May 22, 2026: Biotech Fever Drives Week of Explosive Gains
Market News
David Brooks · May 22, 2026
Friday, May 22, 2026 closes a volatile week dominated by biotech and small-cap explosions. Sunshine...
View All Coverage →
Get LIMN Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Liminatus Pharma, Inc. Class A Common Stock.
Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.